[1]丁 远,王黎洲,宋 杰,等.细胞色素P450酶2C19基因多态性对TIPS术后患者服用氯吡格雷效果的影响 [J].介入放射学杂志,2017,(07):588-593.
 DING Yuan,WANG Lizhou,SONG Jie,et al.The influence of CYP2C19 gene polymorphism on the curative effect of clopidogrel in patients after receiving TIPS[J].journal interventional radiology,2017,(07):588-593.
点击复制

细胞色素P450酶2C19基因多态性对TIPS术后患者服用氯吡格雷效果的影响
()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年07期
页码:
588-593
栏目:
血管介入
出版日期:
2017-07-25

文章信息/Info

Title:
The influence of CYP2C19 gene polymorphism on the curative effect of clopidogrel in patients after receiving TIPS
作者:
丁 远 王黎洲 宋 杰 蒋天鹏 周 石
Author(s):
DING Yuan WANG Lizhou SONG Jie JIANG Tianpeng ZHOU Shi
Department of Interventional Radiology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province 550004, China
关键词:
【关键词】 肝硬化 颈静脉肝内门体分流术 氯吡格雷 细胞色素P450同工酶亚家族2C19 多态性
文献标志码:
A
摘要:
【摘要】 目的 评估细胞色素P450酶2C19(CYP2C19)基因多态性对经颈静脉肝内门体分流术(TIPS)肝硬化患者术后服用氯吡格雷抗血小板治疗的影响。方法 收集2013年1月至2014年12月接受TIPS术治疗的171例肝硬化患者临床资料。所有患者均于术中采集门静脉及肘静脉血液样本并行CYP2C19基因检测。术后每3个月临床随访,比较分析基因检测结果与临床随访结果。结果 110例TIPS术前无输血且术后规律服用氯吡格雷患者纳入本研究。术后平均服用氯吡格雷时间为192.4 d(31~517 d),门静脉血及肘静脉血基因检测结果一致,CYP2C19基因型为*1/*1有49例(44.5%)、*1/*2有27例(24.6%)、*1/*3有18例(16.4%)、*2/*2有11例(10.0%)、*2/*3有3例(2.7%)、*3/*3有2例(1.8%);随访显示慢代谢型基因携带患者分流道功能异常发生率为87.5%(14/16),较中等代谢型患者(20.0%,9/45, χ2=22.9,P=0.006)及快代谢型患者(8.2%,4/49, χ2=37.91,P=0.000 1)明显增高;Cox回归模型多变量分析提示CYP2C19慢代谢型基因变异,是分流道功能异常的重要预测因素(95%CI 1.80~9.03,P=0.000 7)。结论 CYP2C19慢代谢基因变异(*2/*2、*2/*3、*3/*3)是影响TIPS术后患者氯吡格雷治疗效果的重要因素之一,术前检测可为术后提供较为有效的抗血小板治疗方案。

参考文献/References:

[1] Friedman SL. Mechanisms of hepatic fibrogenesis[J]. Gastroen- terology, 2008, 134: 1655- 1669.
[2] Bosch J, Garcia- Pagan JC. Complications of cirrhosis.Ⅰ. Portal hypertension[J]. J Hepatol, 2000, 32(1 Suppl): 141- 156.
[3] 祁兴顺, 韩国宏, 樊代明. 经颈内静脉肝内门体分流术临床应用新进展[J]. 介入放射学杂志, 2011, 20: 499- 504.
[4] Corbett C, Mangat K, Olliff S, et al. The role of Transjugular Intrahepatic Portosystemic Stent- Shunt(TIPSS) in the management of variceal hemorrhage[J]. Liver Int, 2012, 32: 1493- 1504.
[5] Rosch J. Development of transjugular intrahepatic portosystemic shunt[J]. J Vasc Interv Radiol, 2015, 26: 220- 222.
[6] Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J]. J Thromb Haemost, 2007, 5: 2429- 2436.
[7] Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance[J]. Clin Pharmacol Ther, 2008, 84: 236- 242.
[8] Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450[J]. Drug Metab Dispos, 2006, 34: 600- 607.
[9] Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs[J]. Nature, 2001, 409: 202- 207.
[10] Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel[J]. Thromb Haemost, 2000, 84: 891- 896.
[11] Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel[J]. Semin Vasc Med, 2003, 3: 113- 122.
[12] Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss
- of- function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood, 2006, 108: 2244- 2247.
[13] Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome[J]. Am J Cardiol, 2008, 101: 1088- 1093.
[14] Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on- clopidogrel platelet reactivity associated with adverse 1- year clinical outcome of elective percutaneous coronary intervention with drug- eluting or bare- metal stents[J]. J Am Coll Cardiol, 2008, 51: 1925- 1934.
[15] 科技部“十二五”重大专项联合课题组专家. 乙型肝炎病毒相关肝硬化的临床诊断、 评估和抗病毒治疗的综合管理[J]. 国际消化病杂志, 2014, 34: 138- 148.
[16] Mizobe M, Hokimoto S, Akasaka T, et al. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non- diabetic than diabetic patients[J]. Thromb Res, 2014, 134: 72- 77.
[17] Huang Q, Wu X, Fan X, et al. Comparison study of Doppler ultrasound surveillance of expanded polytetrafluoroethylene
- covered stent versus bare stent in transjugular intrahepatic portosystemic shunt[J]. J Clin Ultrasound, 2010, 38: 353- 360.
[18] 唐世伟, 赵新建, 王忠敏, 等. TIPS对比EBL治疗肝硬化食管静脉曲张出血Meta分析[J]. 介入放射学杂志, 2016, 25: 761- 765.
[19] Cura M, Cura A, Suri R, et al. Causes of TIPS dysfunction[J]. AJR Am J Roentgenol, 2008, 191: 1751- 1757.
[20] 陈 斌, 范文哲, 向贤宏, 等. 美国肝病研究学会(AASLD)实践指南: 经颈静脉肝内门体分流术(TIPS)在治疗门脉高压症中的作用[J]. 影像诊断与介入放射学, 2010, 19: 242- 249.
[21] Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study[J]. Lancet, 2009, 373: 309- 317.
[22] Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation[J]. Pharmacogenomics, 2008, 9: 1251- 1259.
[23] Simon T, Verstuyft C, Mary- Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360: 363- 375.
[24] Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J]. JAMA, 2009, 302: 849- 857.
[25] Tatarunas V, Jankauskiene L, Kupstyte N, et al. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy[J]. Blood Coagul Fibrinolysis, 2014, 25: 369- 374.
[26] Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response[J]. J Thromb Haemost, 2013, 11: 1640- 1646.
[27] Gaio V, Nunes B, Fernandes A, et al. Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal[J]. Diabetol Metab Syndr, 2014, 6: 23.
[28] Litos K, Emmanouilidou E, Glynou KM, et al. Rapid genotyping of CYP2D6, CYP2C19 and TPMT polymorphisms by primer extension reaction in a dipstick format[J]. Anal Bioanal Chem, 2007, 389: 1849- 1857.
[29] 曹春鸽, 孙海燕, 周芳芳, 等. 应用HRM技术对CYP2C19*2和CYP2C19*3进行双重SNP分型[J]. 遗传, 2013, 35: 923- 930.
[30] Kim A, Song WK, Kim KR, et al. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles[J]. J Clin Pharm Ther, 2010, 35: 697- 703.
[31] Cervinski MA, Schwab MC, Lefferts JA, et al. Establishment of a CYP2C19 genotyping assay for clinical use[J]. Am J Clin Pathol, 2013, 139: 202- 207.
[32] Park W, Cha IH, Kim CH, et al. Improved patency of transjugular intrahepatic portosystemic shunt: the efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models[J]. Cardiovasc Intervent Radiol, 2007, 30: 719- 724.

相似文献/References:

[1]王 磊,刘福全,岳振东,等. 应用介入技术建立猪肝硬化门脉高压模型的实验研究[J].介入放射学杂志,2012,(09):756.
 WANG Lei,LIU Fu- quan,YUE Zhen- dong,et al. The establishment of liver cirrhosis along with portal hypertension model in experimental pigs by using interventional technique[J].journal interventional radiology,2012,(07):756.
[2]李茂美,程永德,朱西琪.两种不同脾栓方法后门脉压力变化对照研究[J].介入放射学杂志,2014,(10):861.
 LI Mao mei,CHENG Yong de,ZHU Xi qi..Portal pressure changes after partial splenic embolization: comparison study between two embolization methods[J].journal interventional radiology,2014,(07):861.
[3]何创业,祁兴顺,帖 君,等.经颈内静脉肝内门体分流术联合封堵器封堵治疗肝硬化门脉高压伴自发性脾、胃-肾分流[J].介入放射学杂志,2013,(10):801.
 HE Chuang? ye,QI Xing? shun,TIE Jun,et al. Transjugular intrahepatic portosystemic shunt combined with Amplatzer plugging device therapy for cirrhotic portal hypertension with spontaneous spleno?蛳 gastric?蛳 renal shunt[J].journal interventional radiology,2013,(07):801.
[4]刘 新,李奋强,沈世林*,等.TIPS治疗肝硬化乳糜腹水1例[J].介入放射学杂志,2016,(12):1072.
 LIU Xin,LI Fen- qiang,SHEN Shi- lin,et al.Successful treatment of cirrhosis- related chylous ascites with transjugular intrahepatic portosystemic shunt therapy: report of one case[J].journal interventional radiology,2016,(07):1072.
[5]潘 峰,周国锋,梁 斌,等.经皮肝穿刺胃曲张静脉栓塞术联合或不联合部分脾动脉栓塞术治疗急性食管胃底曲张静脉破裂出血临床观察 [J].介入放射学杂志,2018,27(04):316.
 PAN Feng,ZHOU Guofeng,LIANG Bin,et al.Percutaneous transhepatic variceal embolization or together with partial splenic embolization for acute esophagogastric bleeding due to rupture of varicose veins: a clinical observation[J].journal interventional radiology,2018,27(07):316.
[6]陈斯良,胡 朋,林志鹏,等.经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症脾切除断流术后症状复发临床效果 [J].介入放射学杂志,2018,27(04):374.
 CHEN Siliang,HU Peng,LIN Zhipeng,et al.TIPS for the treatment of recurrent symptoms in patients with cirrhotic portal hypertension after splenectomy devascularization: analysis of clinical efficacy[J].journal interventional radiology,2018,27(07):374.
[7]林志鹏,陈斯良,赵剑波.乙型肝炎肝硬化患者肝静脉压力梯度与门静脉压力梯度相关性及临床价值[J].介入放射学杂志,2019,28(02):120.
 LIN Zhipeng,CHEN Siliang,ZHAO Jianbo..The correlation between hepatic venous pressure gradient and portal pressure gradient and its clinical value in patients with hepatitis B cirrhosis[J].journal interventional radiology,2019,28(07):120.
[8]李伟之,郑君仪,于 颖,等.三维打印辅助TIPS治疗肝硬化食管胃底静脉曲张出血[J].介入放射学杂志,2019,28(08):730.
 LI Weizhi,ZHENG Junyi,YU Ying,et al.3D printing- assisted TIPS for the treatment of cirrhotic esophagogastric variceal hemorrhage [J].journal interventional radiology,2019,28(07):730.
[9]陆 孜,潘文秋,赵 卫,等.经颈静脉肝内门体分流术联合部分脾动脉栓塞术对肝硬化脾功能亢进患者肝功能和外周血细胞的中远期影响 [J].介入放射学杂志,2021,30(02):163.
 LU Zi,PAN Wenqiu,ZHAO Wei,et al.Mid-to-long-term effects of TIPS plus PSE on liver functions and peripheral blood cells in patients with cirrhotic hypersplenism[J].journal interventional radiology,2021,30(07):163.
[10]杨 涵,赵 年,李春华,等.医源性腹壁下动脉破裂经皮动脉栓塞1例[J].介入放射学杂志,2021,30(04):343.
 YANG Han,ZHAO Nian,LI Chunhua,et al.Successful treatment of iatrogenic inferior epigastric artery rupture with percutaneous arterial embolization: report of one case[J].journal interventional radiology,2021,30(07):343.
[11]李松蔚,张 捷,闫 东,等.多层螺旋CT及其门静脉造影在TIPS联合胃冠状静脉栓塞术前应用价值[J].介入放射学杂志,2015,(06):476.
 LI Song- wei,ZHANG Jie,YAN Dong,et al.The preoperative application of MSCT and MSCTP in performing TIPS combined with gastric coronary vein embolization[J].journal interventional radiology,2015,(07):476.

备注/Memo

备注/Memo:
(收稿日期:2016-11-12)
(本文编辑:边 佶)
更新日期/Last Update: 2017-07-12